IOVANCE BIOTHERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
IOVA$8.17+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | |
| · · Years Ended December 31, | |||||||||
| · · 2024 · 2023 · 2022 | |||||||||
| Net Loss | | $(372,177) | | $(444,037) | | $(395,893) | |||
| Other comprehensive loss: | | | | ||||||
| Unrealized gain on investments | | 78 | | 940 | | (301) | |||
| Foreign currency translation adjustment | | | (3,650) | | | 2,488 | | | — |
| Comprehensive Loss | | $(375,749) | | $(440,609) | | $(396,194) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.